Cargando…
Oncogenic osteomalacia illustrating the effect of fibroblast growth factor 23 on phosphate homeostasis
In oncogenic osteomalacia (OOM), fibroblast growth factor 23 (FGF23) induces renal phosphate wasting and inhibits the appropriate increase of calcitriol. A patient suffering from OOM is described. Serum calcium, phosphate, biointact parathyroid hormone and intact FGF23 as well as the calcitriol and...
Autores principales: | Westerberg, Per-Anton, Linde, Torbjörn, Vanderschueren, Dirk, Billen, Jaak, Jans, Ivo, Ljunggren, Östen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400509/ https://www.ncbi.nlm.nih.gov/pubmed/26069775 http://dx.doi.org/10.1093/ckj/sfs031 |
Ejemplares similares
-
Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs)
por: Westerberg, Per-Anton, et al.
Publicado: (2013) -
Localization of Oncogenic Osteomalacia by Systemic Venous Sampling of Fibroblast Growth Factor 23
por: Lee, Ji-Yeon, et al.
Publicado: (2017) -
Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor‐Induced Osteomalacia
por: Hartley, Iris R., et al.
Publicado: (2022) -
High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD Stages 3–4: results of a 12-week double-blind, randomized, controlled study
por: Westerberg, Per-Anton, et al.
Publicado: (2018) -
Renal Phosphate Wasting Due to Tumor-Induced (Oncogenic) Osteomalacia
por: Amaratunga, Eluwana A, et al.
Publicado: (2021)